TAVR Platform Drives Sales Growth
TAVR net sales increased 11.3% in Q2, driven by higher sales of the Edwards SAPIEN 3 Ultra RESILIA valve across the U.S., Europe, and Japan; foreign currency tailwinds added $8.4 million.
At the archive date, Edwards Lifesciences Corp was expected to release its Q3 2026 10-Q filing on October 28, 2026, after market close. Last quarter: Edwards Lifesciences delivered strong revenue growth in Q2 FY2026 driven by TAVR and TMTT, but net income fell 27.4% due to a $188.2 million tax valuation allowance.
EPS Estimate
$0.76
Revenue Estimate
$1.73B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the EW page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
TAVR net sales increased 11.3% in Q2, driven by higher sales of the Edwards SAPIEN 3 Ultra RESILIA valve across the U.S., Europe, and Japan; foreign currency tailwinds added $8.4 million.
TMTT net sales surged 47.7% to $198.6 million, propelled by the PASCAL repair system, EVOQUE tricuspid replacement, and SAPIEN M3 mitral valve; the company received CE Mark for SAPIEN M3 RESILIA and FDA approval for TRIFORMIS RESILIA.
The effective tax rate jumped to 53.6% from 16.1% last year, mainly due to a $188.2 million non-cash valuation allowance against California R&D tax credits following budget legislation that permanently limited their utilization; the company also faces ongoing IRS transfer-pricing disputes that could materially impact future periods.
Revenue
$1.74B
+13.63% YoY
EPS (Diluted)
$0.42
-25.00% YoY
Gross Margin
77.5%
-0.1 pts YoY
Operating Income
$513.2M
+24.81% YoY
Add EW to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.